Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch...
-
Upload
martin-gibson -
Category
Documents
-
view
228 -
download
4
Transcript of Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch...
![Page 1: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/1.jpg)
Clinical decisions in the optimization Clinical decisions in the optimization process process
I. Emphasis on tumor control issuesI. Emphasis on tumor control issues
Avi EisbruchAvi Eisbruch
University of MichiganUniversity of Michigan
![Page 2: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/2.jpg)
Standard radiotherapyStandard radiotherapy
Limited ability to control dose distribution Limited ability to control dose distribution across the treated volumeacross the treated volume
Large body of past experience that Large body of past experience that dictates standard care regarding doses dictates standard care regarding doses prescribed to tumors, dose homogeneity, prescribed to tumors, dose homogeneity, and maximal doses allowed to critical and maximal doses allowed to critical organs.organs.
![Page 3: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/3.jpg)
Optimized intensity modulated Optimized intensity modulated radiotherapyradiotherapy
Vastly improved ability to control dose Vastly improved ability to control dose distributions. distributions.
How should we “optimize” dose How should we “optimize” dose distributions?distributions?– The limiting factor is our knowledge of what is The limiting factor is our knowledge of what is
clinically desired. clinically desired.
![Page 4: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/4.jpg)
Optic nerve damageOptic nerve damage
Following definitive, standard RT of Following definitive, standard RT of paranasal sinus cancer: 21/78 (27%) paranasal sinus cancer: 21/78 (27%) patients had unilateral blindness and 4 patients had unilateral blindness and 4 (5%) had bilateral blindness.(5%) had bilateral blindness.– Katz, Mendenhall, et al. Head Neck 2002.Katz, Mendenhall, et al. Head Neck 2002.
![Page 5: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/5.jpg)
Martel et al, IJROBP 1997
3D conformal RT of paranasal sinus cancer
![Page 6: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/6.jpg)
Optic nerve damage following conformal-3D Optic nerve damage following conformal-3D RT of paranasal sinus cancerRT of paranasal sinus cancer
2 cases of blindness out of 20 patients 2 cases of blindness out of 20 patients treated definitively and were free of treated definitively and were free of disease >2 years.disease >2 years.
Parameters for normal tissue complication Parameters for normal tissue complication probabilities (NTCP) were derived from the probabilities (NTCP) were derived from the dosimetric and the clinical data.dosimetric and the clinical data.
Martel et al, 1997
![Page 7: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/7.jpg)
IMRT of paranasal sinus cancer: IMRT of paranasal sinus cancer: sparing the optic nervessparing the optic nerves
“ralatively easy case”
Tsien, Eisbruch, et al, IJROBP 2003
![Page 8: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/8.jpg)
Paranasal sinus cancer: sparing Paranasal sinus cancer: sparing the optic nervesthe optic nerves
Tsien, Eisbruch, et al, IJROBP 2003
![Page 9: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/9.jpg)
Paranasal sinus cancer: sparing Paranasal sinus cancer: sparing the optic nervesthe optic nerves
This was more difficult !
Tsien, Eisbruch, et al, IJROBP 2003
![Page 10: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/10.jpg)
Paranasal sinus cancer: sparing Paranasal sinus cancer: sparing the optic nervesthe optic nerves
Tsien, Eisbruch, et al, IJROBP 2003
![Page 11: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/11.jpg)
Sparing the optic nerves by IMRTSparing the optic nerves by IMRT
While IMRT provides highly conformal While IMRT provides highly conformal dose distributions, trade-offs between dose distributions, trade-offs between organ sparing and target under-dose do organ sparing and target under-dose do exist. exist.
An intelligent choice between these trade-An intelligent choice between these trade-offs cannot be made unless the offs cannot be made unless the parameters of tumor control and parameters of tumor control and complication probability models are known complication probability models are known with a higher certainty. with a higher certainty.
![Page 12: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/12.jpg)
Tumor control vs. DoseTumor control vs. Dose
The most elusive issue due to the large The most elusive issue due to the large heterogeneity in the density of tumor stem heterogeneity in the density of tumor stem cells and their sensitivity to radiation.cells and their sensitivity to radiation.
The doses we prescribe in order to kill The doses we prescribe in order to kill tumors are dictated by the presumed tumors are dictated by the presumed sensitivity of the adjacent normal tissue, sensitivity of the adjacent normal tissue, rather than by the needs to kill the tumor.rather than by the needs to kill the tumor.
![Page 13: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/13.jpg)
A recent exampleA recent example
Locally advanced cancer of the Locally advanced cancer of the nasopharynxnasopharynxMost of the planning treatment volume for Most of the planning treatment volume for the gross, observed disease was the gross, observed disease was encompassed by the desired dose (70 Gy)encompassed by the desired dose (70 Gy)The parts of the tumor adjacent to the The parts of the tumor adjacent to the brain stem received less than the desired brain stem received less than the desired dose to reduce the risk of a severe dose to reduce the risk of a severe complication.complication.
![Page 14: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/14.jpg)
![Page 15: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/15.jpg)
![Page 16: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/16.jpg)
![Page 17: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/17.jpg)
![Page 18: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/18.jpg)
![Page 19: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/19.jpg)
![Page 20: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/20.jpg)
![Page 21: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/21.jpg)
![Page 22: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/22.jpg)
Assessment of the sites of Assessment of the sites of recurrences relative to the dose recurrences relative to the dose
delivereddelivered
![Page 23: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/23.jpg)
CT at time of RecurrenceCT at time of Recurrence
recurrence volume
![Page 24: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/24.jpg)
Transfer of Recurrence VolumeTransfer of Recurrence Volume
Planning CT
recurrence volume
location
50 Gy
60 Gy
![Page 25: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/25.jpg)
Recurrence DefinitionsRecurrence Definitions
% recurrence volume receiving minimal % recurrence volume receiving minimal intended dose intended dose (70 Gy to GTV, 60 to resection bed (70 Gy to GTV, 60 to resection bed or high-risk CTV, 50 to low-risk CTV):or high-risk CTV, 50 to low-risk CTV):
In fieldIn field 95% 95%
MarginalMarginal 20 - 95%20 - 95%
Outside fieldOutside field 20% 20%
![Page 26: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/26.jpg)
0
20
40
60
80Mean Dose
Dos
e (G
y)
Mean Dose to Recurrence VolumesMean Dose to Recurrence VolumesMean Dose to Recurrence VolumesMean Dose to Recurrence Volumes
Recurrence
![Page 27: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/27.jpg)
0
20
40
60
80D
ose
(Gy)
Minimum Dose to Recurrence Minimum Dose to Recurrence VolumesVolumes
Minimum Dose to Recurrence Minimum Dose to Recurrence VolumesVolumes
Recurrence
Minimum Dose
![Page 28: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/28.jpg)
Rouvière, Anatomy of the Human Lymphatic System, Edwards Bros., 1938
![Page 29: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/29.jpg)
Som et al.,Arch. Otolaryngol.Head Neck Surg.1999
Neck Node Levels
![Page 30: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/30.jpg)
Update: Pattern of failureUpdate: Pattern of failure
160 patients treated with IMRT since 1994160 patients treated with IMRT since 1994
24 local-regional failures24 local-regional failures
20 in-field 20 in-field
All 4 marginal failures can be explained by All 4 marginal failures can be explained by the clinical decisions that had been made the clinical decisions that had been made regarding the targets.regarding the targets.
![Page 31: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/31.jpg)
Most failures are in-fieldMost failures are in-field
Should we escalate the dose?Should we escalate the dose?
Would dose inhomogeneities (“hot spots”) Would dose inhomogeneities (“hot spots”) within the targets help improve tumor within the targets help improve tumor control?control?– Fowler, Deasy: modeling: Over-dosage in part Fowler, Deasy: modeling: Over-dosage in part
of the target may compensate for volumes of of the target may compensate for volumes of underdosage within the target (as long as underdosage within the target (as long as these volumes are not too large)these volumes are not too large)
![Page 32: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/32.jpg)
Xia et al, IJROBP 2000
Over-dosing the GTV
![Page 33: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/33.jpg)
In addition to the nominal In addition to the nominal dose…dose…
““Hot volumes” in a highly nonuniform plan Hot volumes” in a highly nonuniform plan are delivered at a higher dose/fraction are delivered at a higher dose/fraction than the prescribed dose. than the prescribed dose.
The biologically equivalent dose in the hot The biologically equivalent dose in the hot volume is higher than the DVH impliesvolume is higher than the DVH implies– 80 Gy over 35 treatments: 2.3 Gy/fraction, 80 Gy over 35 treatments: 2.3 Gy/fraction,
NTD=85 Gy. NTD=85 Gy.
![Page 34: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/34.jpg)
Where are the “hot spots” locatedWhere are the “hot spots” located
![Page 35: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/35.jpg)
Change in Target Homogeneity
0
20
40
60
80
100
0 20 40 60 80Dose (Gy)
% V
olu
me
00111ep P2
PTV66ContraParotid
+/-5%
+/-20%
+/-10%
Vineberg et al.
![Page 36: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/36.jpg)
Tumor Control Probability vs. Treatment Delivery Time
JZ Wang et al, IJROBP 2003
![Page 37: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/37.jpg)
Should limiting treatment time be Should limiting treatment time be incorporated into the treatment incorporated into the treatment
optimization process?optimization process?
![Page 38: Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.](https://reader036.fdocuments.us/reader036/viewer/2022081506/56649f055503460f94c1aec2/html5/thumbnails/38.jpg)
Interim conclusionsInterim conclusions
The pattern of recurrence in our and other The pattern of recurrence in our and other series suggests that dose escalation to all series suggests that dose escalation to all or parts of the targets at highest risk of or parts of the targets at highest risk of failure may improve tumor control. failure may improve tumor control.
This is supported by models of tumor This is supported by models of tumor control probability (TCP)control probability (TCP)
Clinical validation is still lacking. Clinical validation is still lacking.